SCNI — Scinai Immunotherapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $1.89m
- $5.81m
- $0.66m
- 34
- 94
- 27
- 50
Annual balance sheet for Scinai Immunotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | 10-K | 20-F | 20-F |
| Standards: | IFRS | IFRS | USG | USG | USG |
| Status: | fx Final | fx Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 2.93 | 17.4 | 14.1 | 4.87 | 1.96 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.375 | 0.326 | — | — | 0.083 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3.31 | 17.7 | 14.4 | 5.45 | 2.39 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 14.3 | 14.2 | 12.7 | 12 | 11.1 |
| Other Long Term Assets | |||||
| Total Assets | 17.7 | 32.1 | 27.1 | 17.5 | 13.4 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 20 | 2.32 | 2.34 | 1.78 | 1.81 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 22.3 | 24.6 | 28.8 | 22 | 3.47 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -4.55 | 7.52 | -1.76 | -4.57 | 9.98 |
| Total Liabilities & Shareholders' Equity | 17.7 | 32.1 | 27.1 | 17.5 | 13.4 |
| Total Common Shares Outstanding |